Navigation Links
Cumberland Pharmaceuticals Reports 2012 Annual Financial Results

NASHVILLE, Tenn., Feb. 28, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results.

Net Revenue:  For the three months ended December 31, 2012, net revenue was $13.7 million, up from $13.0 million in the prior year period.

For the year ended December 31, 2012, net revenues were $48.9 million, compared with $51.1 million for 2011.

Operating Expenses:  Total operating expenses for the three months ended December 31, 2012 were $10.4 million compared to $11.3 million the prior year period. During the fourth quarter of 2012, operating expenses included $0.7 million of non-recurring expenses associated with the realignment of our sales organization.

For the year ended December 31, 2012, total operating expenses were approximately $40.0 million compared with $41.3 million for 2011.

Net Income:  Net income attributable to common shareholders for the three months ended December 31, 2012, was $1.8 million, or $0.09 per diluted share, compared to $0.9 million, or $0.04 per diluted share, for the same period in 2011. This increase resulted from quarter- over-quarter sales growth along with reduced expenses.

Net income attributable to common shareholders for the year ended December 31, 2012 increased to $5.8 million, or $0.30 per diluted share, compared to $5.7 million, or $0.28 per diluted share, for 2011. After excluding the one-time sales realignment expenses, adjusted diluted earnings per share were $0.32. (1)

Balance Sheet: As of December 31, 2012, Cumberland had $71.0 million in cash and marketable securities, compared to $70.6 million at the end of 2011. Total assets at December 31, 2012, were $98.6 million compared to $95.5 million in 2011. At December 31, 2012, Cumberland had total loans of $4.4 million, down from $4.9 million at the end of 2011. Shareholders' equity increased to $85.7 million at the end of 2012 from $82.9 million for the prior period.

"We are pleased with the progress we made in 2012 as highlighted by our financial results, as well as several product milestones, including the expansion of our international presence, the completion of four Caldolor studies, and the allowance of two new Acetadote patents," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "As we move into 2013, we will continue to maximize our near term opportunities while laying the foundation for the long term expansion, diversification and success of our business."

Product HighlightsAcetadote®

In November 2012, Cumberland received a Notice of Allowance from the United States Patent and Trademark Office for a second patent relating to the new formulation of Acetadote. The new patent will include claims regarding the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose and will expire in August 2025.

Cumberland also entered into a Settlement Agreement with Paddock Laboratories, LLC and Perrigo Company in November to resolve the challenges and pending litigation between the Company and each of Paddock and Perrigo involving the Acetadote patent. Under the Settlement Agreement, Paddock and Perrigo admit that the Acetadote patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote product (with or without EDTA) would infringe upon the Acetadote patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the Acetadote patent through its expiration currently scheduled for May 2026.

The Company has also entered into a License and Supply Agreement with Paddock and Perrigo. Under the terms of the License and Supply Agreement, if a third party receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party has made such generic version available for purchase in commercial quantities in the United States, the Company will supply Perrigo with an authorized generic version of the Company's Acetadote product.

In January 2013, Perrigo announced initial distribution of Cumberland's authorized generic acetylcysteine injection product.


Cumberland is pleased to announce new top-line results from a pilot clinical study evaluating the safety and analgesic efficacy of Caldolor (ibuprofen) Injection compared to ketorolac injection in treating pain following knee arthroscopy procedures in adult patients.

Fifty-one patients were enrolled at The Ohio State Medical Center. Compared to patients receiving ketorolac, patients receiving intravenous ibuprofen experienced less postoperative pain prior to discharge. Patients receiving Caldolor also needed fewer narcotics and were less likely to require narcotics prior to discharge. This data supports the benefits of using Caldolor in a pre-emptive model of multimodal analgesia.

These positive results follow the February release of two recent studies affirming the safety and efficacy of Caldolor in treating pain and fever in adult patients when administered over a shortened infusion time. Top-line results from these two registry studies involved 450 patients who received Caldolor at 34 leading medical centers throughout the United States.

The Company continued to expand the international market for Caldolor through strategic partnerships. In December 2012, the application for regulatory approval of Caldolor for fever in Australia by Cumberland's partner Phebra Pty Ltd., was approved.

In January 2013, Cumberland entered into agreements with India's Sandor Medicaids Pvt. Ltd. and Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the commercialization of Caldolor in those countries.

Company UpdateIn November 2012, Cumberland completed a realignment of its national sales organization to more efficiently cover key targets in support of all three marketed products, Caldolor, Acetadote and Kristalose, in the United States.

Conference Call and WebcastA conference call and live Internet webcast will be held on Thursday, February 28, 2013 at 4:30 p.m. Eastern Time to discuss the Company's fourth quarter 2012 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 97366269. The live webcast and rebroadcast can be accessed via Cumberland's website at

About Cumberland PharmaceuticalsCumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at  

About AcetadoteAcetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit

About CaldolorCaldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit

About KristaloseKristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit

Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets

December 31, 2012 and 201120122011ASSETSCurrent assets:Cash and cash equivalents$


70,599,146Marketable securities16,686,136—Accounts receivable, net of allowances6,017,2017,082,890Inventories6,218,3555,774,694Prepaid and other current assets1,671,0911,627,455Deferred tax assets2,290,0782,223,882Total current assets87,232,24287,308,067Property and equipment, net1,188,9141,119,339Intangible assets, net9,476,7987,023,064Deferred tax assets50,411—Other assets645,36667,846Total assets$


95,518,316LIABILITIES AND EQUITYCurrent liabilities:Accounts payable$


1,513,548Accrued liabilities5,264,8065,086,400Total current liabilities8,055,3606,599,948Revolving line of credit4,359,9514,859,951Deferred tax liability—645,029Other long-term liabilities611,933578,119Total liabilities13,027,24412,683,047Commitments and contingenciesEquity:Shareholders' equity:Common stock – no par value; 100,000,000 shares authorized;
8,937,107 and 20,020,535 shares issued and outstanding as of
December 31, 2012 and 2011, respectively67,197,16770,272,155Retained earnings18,499,15412,656,662Total shareholders' equity85,696,32182,928,817Noncontrolling interests(129,834)(93,548)Total equity85,566,48782,835,269Total liabilities and equity$



Condensed Consolidated Statements of Income

(unaudited)Three months ended
December 31,Years endedDecember 31,2012201120122011Revenues:Net product revenue$




50,893,794Other revenue59,033248,982907,206248,982Net revenues13,696,36613,031,83048,851,23751,142,776Costs and expenses:Cost of products sold2,172,7621,951,2005,046,1795,362,554Selling and marketing4,942,4254,686,48620,329,49320,940,060Research and development441,2151,758,3265,095,1725,028,072General and administrative2,765,0562,784,4279,096,1659,307,301Amortization121,915140,122466,126655,302Total costs and expenses10,443,37311,320,56140,033,13541,293,289Operating income3,252,9931,711,2698,818,1029,849,487Interest income48,79163,099304,865210,727Interest expense(15,616)(24,460)(71,985)(353,497)Income before income taxes3,286,1681,749,9089,050,9829,706,717Income tax expense(1,492,213)(841,783)(3,244,776)(4,080,204)Net income1,793,955908,1255,806,2065,626,513Net loss at subsidiary attributable to noncontrolling interests11,5453,54036,28631,343Net income attributable to common shareholders$




5,657,856Earnings per share attributable to common shareholders:Basic$








0.28Weighted-average shares outstanding:Basic19,048,94520,130,21119,564,62520,342,913Diluted19,245,04720,318,17619,787,53720,572,132 

Condensed Consolidated Statements of Cash Flows

Years ended December 31, 2012 and 2011
20122011Cash flows from operating activities:Net income$


5,626,513Adjustments to reconcile net income to net cash flows provided by operating activities:Depreciation and amortization expense901,6491,040,407Deferred tax expense (benefit)(829,846)1,665,110Share-based compensation636,528779,305Excess tax benefit derived from exercise of stock options(3,760,766)(2,355,345)Noncash interest expense24,075137,487Noncash investment gains(45,814)—Net changes in assets and liabilities affecting operating activities:Accounts receivable1,065,689(1,937,396)Inventory(443,661)1,909,148Prepaid, other current assets and other assets(648,941)(399,393)Accounts payable and other accrued liabilities4,373,2762,296,535Other long-term liabilities56,787(40,224)Net cash provided by operating activities7,135,1828,722,147Cash flows from investing activities:Additions to property and equipment(464,893)(257,502)Additions to intangibles(2,071,926)(180,269)Proceeds from sale of marketable securities5,220,480—Purchases of marketable securities(21,860,802)—Net cash used in investing activities(19,177,141)(437,771)Cash flows from financing activities:Net borrowings (repayments) on line of credit(500,000)3,034,000Principal payments on note payable—(5,333,333)Payments made in connection with repurchase of common shares(8,086,594)(4,247,440)Costs of financing for long-term debt and credit facility—(17,637)Proceeds from exercise of stock options618,022629,865Excess tax benefit derived from exercise of stock options3,760,7662,355,345Net cash used in financing activities(4,207,806)(3,579,200)Net increase (decrease) in cash and cash equivalents(16,249,765)4,705,176Cash and cash equivalents, beginning of year70,599,14665,893,970Cash and cash equivalents, end of year$



Reconciliation of Net Income Attributable to Common Shareholders to Adjusted Net Income
Attributable to Common Shareholders and Adjusted Earnings Per Share Attributable to Common
(unaudited)Three months ended
December 31,Years ended
December 31,2012201120122011Net income attributable to common shareholders$




5,657,856Costs associated with sales force realignment**685,267—685,267—Income tax effect of sales force realignment costs(277,533)—(277,533)—Net costs of sales force realignment407,734—407,734—Adjusted net income attributable to common shareholders$




5,657,856Adjusted earnings per share attributable to
common shareholders:Basic$








0.28Weighted-average shares outstanding:Basic19,048,94520,130,21119,564,62520,342,913Diluted19,245,04720,318,17619,787,53720,572,132**  On November 29, 2012, Cumberland Pharmaceuticals Inc. (the "Company") implemented a realignment of its national sales organization to more efficiently cover key targets in support of its three marketed products, Caldolor, Acetadote and Kristalose . As a result of this realignment the Company's sales personnel totaling 64 individuals, consolidated into 8 nationwide districts. The Company does not expect to have further changes to its sales personnel as a result of the realignment. The costs associated with the sales force realignment are one-time expenses recorded during the fourth quarter ending December 31, 2012.  As management believes these costs are nonrecurring and important to understanding the Company's business operations, it has presented these separately.

The Company provided the above adjusted financial performance measures, which are considered "non-GAAP" financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The definition of these non-GAAP measures may differ from similarly titled measures used by others.

Management believes these non-GAAP financial performance measures are important as they eliminate nonrecurring sales realignment costs. The Company used these non-GAAP financial measures to facilitate management's internal comparisons of the Company's operating results, as well as to reconcile to guidance provided to investors. In addition, the use of non-GAAP financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.  The Company defines these non-GAAP financial measures as follows:

  • Adjusted net income attributable to common shareholders: net income attributable to common shareholders adjusted for the one-time expenses associated with the sales force realignment during the fourth quarter ending December 31, 2012, net of related income tax effect.
  • Adjusted basic earnings per share: adjusted net income attributable to common shareholders divided by basic weighted-average shares outstanding.
  • Adjusted diluted earnings per share: adjusted net income attributable to common shareholders divided by diluted weighted-average shares outstanding.


    SOURCE Cumberland Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
    2. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
    3. Cumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 2012
    4. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
    5. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
    6. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. Cumberland Emerging Technologies Expands Life Sciences Center
    8. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
    9. Cumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
    10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    Post Your Comments:
    (Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
    (Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
    (Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
    (Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
    (Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
    (Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
    Breaking Medicine News(10 mins):